CRF-2 antagonists (Neurocrine/GlaxoSmithKline)

N/A

Report date: 2025/03/19 20:00:56
NME

Base Information

Drug NameCRF-2 antagonists (Neurocrine/GlaxoSmithKline)
Drug Alias Namecompound 358-086-15anxiety therapy (Neurocrine/GSK)eating disorder therapy (Neurocrine/GSK)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCorticotropin-releasing factor receptor 2 antagonists
TargetsCorticotropin-releasing factor receptor 2
Therapy Area/IndicationsFeeding and Eating DisordersAnxiety Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNeurocrine Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline PlcNeurocrine Biosciences Inc
Active IndicationsN/A
Inactive IndicationsFeeding and Eating DisordersAnxiety Disorders

Other Information

ATC CodeN/A
Related LinksN/A